133 related articles for article (PubMed ID: 15536342)
21. Improved detection of p53 point mutations by dideoxyfingerprinting (ddF).
Martincic D; Whitlock JA
Oncogene; 1996 Nov; 13(9):2039-44. PubMed ID: 8934553
[TBL] [Abstract][Full Text] [Related]
22. Analysis of the K-ras and p53 pathways in X-ray-induced lung tumors in the rat.
Belinsky SA; Middleton SK; Picksley SM; Hahn FF; Nikula KJ
Radiat Res; 1996 Apr; 145(4):449-56. PubMed ID: 8600505
[TBL] [Abstract][Full Text] [Related]
23. Correlation of mutation and immunohistochemistry of p53 in hepatocellular carcinomas in Korean people.
Lee SN; Park CK; Sung CO; Choi JS; Oh YL; Cho JW; Yoo BC
J Korean Med Sci; 2002 Dec; 17(6):801-5. PubMed ID: 12483005
[TBL] [Abstract][Full Text] [Related]
24. Oncogenic pathway of sporadic colorectal cancer with novel germline missense mutations in the hMSH2 gene.
Yamada K; Zhong X; Kanazawa S; Koike J; Tsujita K; Hemmi H
Oncol Rep; 2003; 10(4):859-66. PubMed ID: 12792735
[TBL] [Abstract][Full Text] [Related]
25. A universal method for the mutational analysis of K-ras and p53 gene in non-small-cell lung cancer using formalin-fixed paraffin-embedded tissue.
Sarkar FH; Valdivieso M; Borders J; Yao KL; Raval MM; Madan SK; Sreepathi P; Shimoyama R; Steiger Z; Visscher DW
Diagn Mol Pathol; 1995 Dec; 4(4):266-73. PubMed ID: 8634783
[TBL] [Abstract][Full Text] [Related]
26. Detection of p53 mutations in hematological malignancies: comparison between immunocytochemistry and DNA analysis.
Lepelley P; Preudhomme C; Vanrumbeke M; Quesnel B; Cosson A; Fenaux P
Leukemia; 1994 Aug; 8(8):1342-9. PubMed ID: 8057671
[TBL] [Abstract][Full Text] [Related]
27. Analysis of p53, K-ras-2, and C-raf-1 in pulmonary neuroendocrine tumors. Correlation with histological subtype and clinical outcome.
Przygodzki RM; Finkelstein SD; Langer JC; Swalsky PA; Fishback N; Bakker A; Guinee DG; Koss M; Travis WD
Am J Pathol; 1996 May; 148(5):1531-41. PubMed ID: 8623922
[TBL] [Abstract][Full Text] [Related]
28. p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer.
Esrig D; Spruck CH; Nichols PW; Chaiwun B; Steven K; Groshen S; Chen SC; Skinner DG; Jones PA; Cote RJ
Am J Pathol; 1993 Nov; 143(5):1389-97. PubMed ID: 7901994
[TBL] [Abstract][Full Text] [Related]
29. New insights into p53 protein stabilisation in oral squamous cell carcinoma.
Partridge M; Kiguwa S; Emilion G; Pateromichelakis S; A'Hern R; Langdon JD
Oral Oncol; 1999 Jan; 35(1):45-55. PubMed ID: 10211310
[TBL] [Abstract][Full Text] [Related]
30. Dukes B colorectal cancer: distinct genetic categories and clinical outcome based on proximal or distal tumor location.
Gervaz P; Bouzourene H; Cerottini JP; Chaubert P; Benhattar J; Secic M; Wexner S; Givel JC; Belin B
Dis Colon Rectum; 2001 Mar; 44(3):364-72; discussion 372-3. PubMed ID: 11289282
[TBL] [Abstract][Full Text] [Related]
31. P53 expression, p53 and Ha-ras mutation and telomerase activation during nitrosamine-mediated hamster pouch carcinogenesis.
Chang KW; Sarraj S; Lin SC; Tsai PI; Solt D
Carcinogenesis; 2000 Jul; 21(7):1441-51. PubMed ID: 10874024
[TBL] [Abstract][Full Text] [Related]
32. [The comparison of sensitivity between immunostaining and a simplified PCR-cold SSCP method in p53 genomic mutations].
Ueno I; Ota H; Hidaka E; Ishikawa M; Hirota M; Nara K; Katsuyama T
Rinsho Byori; 2000 May; 48(5):469-72. PubMed ID: 10892297
[TBL] [Abstract][Full Text] [Related]
33. Co-mutation of p53, K-ras genes and accumulation of p53 protein and its correlation to clinicopathological features in rectal cancer.
Pan ZZ; Wan DS; Chen G; Li LR; Lu ZH; Huang BJ
World J Gastroenterol; 2004 Dec; 10(24):3688-90. PubMed ID: 15534934
[TBL] [Abstract][Full Text] [Related]
34. Relationship between p53 gene mutation and protein expression: clinical significance in transitional cell carcinoma of the bladder.
Gao JP; Uchida T; Wang C; Jiang SX; Matsumoto K; Satoh T; Minei S; Soh S; Kameya T; Baba S
Int J Oncol; 2000 Mar; 16(3):469-75. PubMed ID: 10675477
[TBL] [Abstract][Full Text] [Related]
35. p53 abnormalities in primary prostate cancer: single-strand conformation polymorphism analysis of complementary DNA in comparison with genomic DNA. The Cooperative Prostate Network.
Gumerlock PH; Chi SG; Shi XB; Voeller HJ; Jacobson JW; Gelmann EP; deVere White RW
J Natl Cancer Inst; 1997 Jan; 89(1):66-71. PubMed ID: 8978408
[TBL] [Abstract][Full Text] [Related]
36. K-ras and p53 mutations in aberrant crypt foci and colonic tumors from colon cancer patients.
Shivapurkar N; Huang L; Ruggeri B; Swalsky PA; Bakker A; Finkelstein S; Frost A; Silverberg S
Cancer Lett; 1997 May; 115(1):39-46. PubMed ID: 9097977
[TBL] [Abstract][Full Text] [Related]
37. P53 and MDM2 co-expression in tobacco and betel chewing-associated oral squamous cell carcinomas.
Shwe M; Chiguchi G; Yamada S; Nakajima T; Maung KK; Takagi M; Amagasa T; Tsuchida N
J Med Dent Sci; 2001 Dec; 48(4):113-9. PubMed ID: 12160248
[TBL] [Abstract][Full Text] [Related]
38. p53 mutations in chondrosarcoma.
Terek RM; Healey JH; Garin-Chesa P; Mak S; Huvos A; Albino AP
Diagn Mol Pathol; 1998 Feb; 7(1):51-6. PubMed ID: 9646035
[TBL] [Abstract][Full Text] [Related]
39. Frequent expression of Bcl-2 in renal-cell carcinomas carrying wild-type p53.
Tomita Y; Bilim V; Kawasaki T; Takahashi K; Okan I; Magnusson KP; Wiman KG
Int J Cancer; 1996 May; 66(3):322-5. PubMed ID: 8621251
[TBL] [Abstract][Full Text] [Related]
40. Frequent p53 gene mutations in serrated adenomas of the colorectum.
Hiyama T; Yokozaki H; Shimamoto F; Haruma K; Yasui W; Kajiyama G; Tahara E
J Pathol; 1998 Oct; 186(2):131-9. PubMed ID: 9924427
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]